Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative medications function by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these agents increase insulin production and suppress gluca

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing variations in their ph